A recent interesting study has been shown that nearly 70–75% of SCLC patients samples have dysregulated cell cycle [56], suggesting that the targeting of FOXM1 would be beneficial to leads to cell cycle arrest in SCLC cells. Here, FOXM1 is linked to small cell lung carcinoma.